Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. The announcement, made earlier this week, signals a significant regulatory milestone for the company as it advances a potential new tool in the fight against a tick-borne illness that affects hundreds of thousands of Americans annually.
The planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons to evaluate the prevention of Lyme disease through six months after dosing. Manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027. TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart, with the potential to provide protection throughout the U.S. Lyme disease season.
This development is important because Lyme disease is the most common vector-borne disease in the United States, with an estimated 476,000 people diagnosed and treated each year, according to the Centers for Disease Control and Prevention. Current prevention strategies rely primarily on tick avoidance and early antibiotic treatment, but no vaccine is currently available for humans. TNX-4800, if successful, could offer a new approach by providing passive immunity through a monoclonal antibody that targets the OspA protein on the Lyme disease bacterium, potentially preventing infection after a tick bite.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved for fibromyalgia, marking the first new treatment for the condition in more than 15 years. Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®.
The company is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The FDA feedback provides a clear path forward for the Phase 2 study, which is a critical step in the development of TNX-4800. The adaptive design allows for modifications based on interim data, potentially speeding up the development process. With manufacturing on track, Tonix is positioning itself to initiate the study in the near term, subject to final protocol alignment with the FDA.
For more information on the full press release, visit https://ibn.fm/pe0eP. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP.
